{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:43:15Z","timestamp":1761100995268},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,3,17]],"date-time":"2009-03-17T00:00:00Z","timestamp":1237248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00277-009-0730-x","type":"journal-article","created":{"date-parts":[[2009,3,16]],"date-time":"2009-03-16T15:06:42Z","timestamp":1237216002000},"page":"1141-1144","source":"Crossref","is-referenced-by-count":8,"title":["Repeated responses of an elderly patient with high-risk myelodysplastic syndrome to sequential therapy with tipifarnib, 5-azacitidine, and decitabine"],"prefix":"10.1007","volume":"88","author":[{"given":"Isabel","family":"M\u00f6ller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norbert","family":"Gattermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Habersang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Kuendgen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,17]]},"reference":[{"key":"730_CR1","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","volume":"109","author":"P Fenaux","year":"2007","unstructured":"Fenaux P, Raza P, GJi Muft, Aul C, Germing U, Kantarijan H, Cripe L, Kerstens R, De Porre P, Kurzrock R (2007) A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate to high risk mds. Blood 109:4158\u20134163. doi: 10.1182\/blood-2006-07-035725","journal-title":"Blood"},{"key":"730_CR2","doi-asserted-by":"crossref","unstructured":"Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, Schoch R, List AF, Gore SD, Seymour JF, Hellstrom-Lindberg E, Bennet JM, Byrd JC, Backstrom JT, Zimmermann LS, McKenzie DR, Beach CL, Silverman LR (2007) Azacitidine treatment prolongs overall survival in higher-risk MDS patients compared with conventional care regimes: results of the aza-001 phase III study. Blood 110:817. Abstract","DOI":"10.1182\/blood.V110.11.817.817"},{"key":"730_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2402330","volume":"16","author":"C Strupp","year":"2002","unstructured":"Strupp C, Germing U, Aivado M, Misgeld E, Haas R, Gattermann N (2002) Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 16:1\u20136. doi: 10.1038\/sj.leu.2402330","journal-title":"Leukemia"},{"key":"730_CR4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V98.4.958","volume":"98","author":"A Raza","year":"2001","unstructured":"Raza A, Meyer P, Dutt D (2001) Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98:958\u2013965. doi: 10.1182\/blood.V98.4.958","journal-title":"Blood"},{"key":"730_CR5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.leukres.2003.08.007","volume":"28","author":"P Musto","year":"2004","unstructured":"Musto P (2004) Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 28:325\u2013332. doi: 10.1016\/j.leukres.2003.08.007","journal-title":"Leuk Res"},{"key":"730_CR6","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1200\/JCO.1999.17.3.1071","volume":"17","author":"DM Beaupre","year":"1999","unstructured":"Beaupre DM, Kurzrock R (1999) Ras and leukemia: from basic mechanisms to gene-directed therapy. J Clin Oncol 17:1071","journal-title":"J Clin Oncol"},{"issue":"39","key":"730_CR7","doi-asserted-by":"crossref","first-page":"30451","DOI":"10.1074\/jbc.M003469200","volume":"275","author":"HR Ashar","year":"2000","unstructured":"Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P (2000) Farnesyl transferaseinhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 275(39):30451\u201330457. doi: 10.1074\/jbc.M003469200","journal-title":"J Biol Chem"},{"key":"730_CR8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1158\/1078-0432.CCR-07-1532","volume":"14","author":"R Kurzrock","year":"2008","unstructured":"Kurzrock R, Kantarijan HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM (2008) Phase I Study of alternate-week administration of tipifarnib in patients with MDS. Clin Cancer Res 14:509\u2013514. doi: 10.1158\/1078-0432.CCR-07-1532","journal-title":"Clin Cancer Res"},{"key":"730_CR9","first-page":"A12","volume":"68","author":"LR Silverman","year":"1994","unstructured":"Silverman LR, Holland JF, Demakos EP (1994) Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921. Ann Hematol 68:A12","journal-title":"Ann Hematol"},{"key":"730_CR10","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429\u20132440. doi: 10.1200\/JCO.2002.04.117","journal-title":"J Clin Oncol"},{"key":"730_CR11","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarijan","year":"2006","unstructured":"Kantarijan H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794\u20131803. doi: 10.1002\/cncr.21792","journal-title":"Cancer"},{"key":"730_CR12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1182\/blood-2006-05-021162","volume":"109","author":"H Kantarijan","year":"2007","unstructured":"Kantarijan H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52\u201357. doi: 10.1182\/blood-2006-05-021162","journal-title":"Blood"},{"key":"730_CR13","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/sj.leu.2400526","volume":"11","author":"PW Wijermans","year":"1997","unstructured":"Wijermans PW, Krulder JW, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2\u00b4-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11:S19\u2013S23. doi: 10.1038\/sj.leu.2400526","journal-title":"Leukemia"},{"key":"730_CR14","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1200\/JCO.2000.18.5.956","volume":"18","author":"PW Wijermans","year":"2000","unstructured":"Wijermans PW, L\u00fcbbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Low-dose 5-Aza-2\u00b4-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956\u2013962","journal-title":"J Clin Oncol"},{"issue":"4","key":"730_CR15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1080\/10428190701882146","volume":"49","author":"G Borthakur","year":"2008","unstructured":"Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H (2008) Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 49(4):690\u2013695. doi: 10.1080\/10428190701882146","journal-title":"Leuk Lymphoma"},{"key":"730_CR16","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2003-12-4333","volume":"104","author":"A Kuendgen","year":"2004","unstructured":"Kuendgen A, Strupp C, Aivado M, Bernhardt A, Hildebrandt B, Haas R, Germing U, Gattermann N (2004) Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid. Blood 104:1266\u20131269. doi: 10.1182\/blood-2003-12-4333","journal-title":"Blood"},{"key":"730_CR17","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/cncr.22891","volume":"110","author":"A Kuendgen","year":"2007","unstructured":"Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancie. Cancer 110:943\u2013995. doi: 10.1002\/cncr.22891","journal-title":"Cancer"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0730-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-009-0730-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-009-0730-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T20:44:58Z","timestamp":1589661898000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-009-0730-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,17]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["730"],"URL":"https:\/\/doi.org\/10.1007\/s00277-009-0730-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,17]]}}}